Business News

Thailand launches coronavirus vaccine development

Thailand launches its Covid-19 vaccine program on Monday, mainly at the Oxford / AstraZeneca jab manufactured by Siam Bioscience, a non-vaccinated King Maha Vajiralongkorn company.

The release is particularly important to the Prayuth Chan-ocha government, which is facing growing public outrage from individuals and businesses due to delays in vaccination, as well as AstraZeneca, which has designated Thailand as the capital of Southeast Asia.

Siam Bioscience will generate 200m of coronavirus, including exports.

Thailand is struggling with a the spread of disease about 2,000-4,000 report new cases a day – the largest since the plague began.

Like their district counterparts Vietnam and Taiwan, the empire introduced Covid-19 to zero Infectious Diseases in 2020. The trauma of the case was triggered by several species of coronavirus that have spread rapidly in markets, prisons, and labor camps.

But there have been signs of delays in production at Siam Bioscience. Philippines He said Last week the first batch of 17m levels expected from Thailand was delayed and reduced.

Separately, the Rural Doctors Society of Thailand says the government is importing 500,000 AstraZeneca vaccines from South Korea to address the shortage of jobs. Some Thais have been told they can expect to be vaccinated in June but will be advised later that they will be vaccinated.

Thai government last week received delivery of a 1.8m jab from AstraZeneca, the first 6m vaccine to come this month. It also said that broadcasting was about to end but a spokesman for the government declined to comment on a question from the Financial Times about whether to use jabs from South Korea as well as those made locally. Siam Bioscience declined to comment and AstraZeneca’s Thailand office did not respond to a request for comment.

Thai Enquirer, a trusted online publisher, last week called Siam Bioscience a “global shame”.

“Although Serum Institute in India is facing challenges, so it would be a mistake to expect all of Siam Bioscience’s products to be as efficient as silk, “said Pavida Pananond, a professor of international business at Thammasat Business School, referring to a vaccine manufacturer in India.” very much. ”

As the disease progressed earlier this year, the Thai government was accused of relying too much on a single vaccine developed by those who introduced the first vaccine. More recently, it has moved up jabs from other suppliers including Sinovac, a Chinese pharmaceutical company, BioNTech / Pfizer, and Johnson & Johnson, a US pharmaceutical manufacturer.

Thais rights against Siam Bioscience have failed because the billionaire king is his, as well as insulting the royal family.

Thanathorn Juangroongruangkit, Thailand’s most vocal activist, was charged with advertising and “computer lawsuits” in January after an online comment on the so-called “royal vaccine”.

The 69-year-old Thai monarch’s power and wealth were met with outrage by those who led the youth last year demonstrations of democracy.

Additional reports of Ryn Jirenuwat reports in Bangkok

Follow me on Twitter: @JohnReedwrites

Recent cases of coronavirus

Follow FT’s description of the global epidemic and the rapidly changing economic crisis Pano.

Source link

Related Articles

Leave a Reply

Back to top button